CVS sues Tennessee after Gov. Bill Lee signs Fair RX Act
CVS is suing the State of Tennessee to block the new FAIR Rx Act, which prohibits pharmacy benefits managers from running pharmacies they own. The company claims the law, signed by Gov. Bill Lee, would force it to close all 134 of its community pharmacies in the state, impacting 2,000 employees and 1.5 million patients. A state audit previously revealed that CVS Caremark paid affiliated pharmacies significantly more for medications than unaffiliated ones.
CVS Health Faces 340B Lawsuits As Stock Rally And Valuation Scrutinized
CVS Health is currently facing multiple federal lawsuits from major hospital systems, alleging the company withheld about $250 million in 340B drug discount savings. These lawsuits scrutinize CVS Health's pharmacy benefit management practices at a time when its stock has seen significant growth. Investors are advised to consider how potential legal outcomes, settlements, or policy changes could impact CVS Health's financial performance and PBM segment, especially given its P/E ratio relative to the industry and existing debt coverage risks.
Hospitals Take CVS to Court Over Alleged $250M 340B Scheme
Three health systems—Mount Sinai, Michigan Medicine, and the University of Kansas Health System—have filed lawsuits against CVS Health. They allege that CVS's pharmacy benefit manager, CVS Caremark, diverted approximately $250 million in savings from the 340B Drug Pricing Program between 2020 and 2025 through "spread pricing." The hospitals claim these funds were meant to support care for vulnerable patients and are seeking accountability and recovery of the diverted money.
UnitedHealth Group’s AI Push Tests Cost Control And Competitive Edge
UnitedHealth Group is investing US$1.6 billion this year into AI initiatives, including the rollout of its generative AI chatbot, Avery, to improve cost control and operational efficiency. This move comes after a challenging 2025 and aims to automate tasks in areas like member support and claims, positioning the company competitively in healthcare services. Investors should monitor how effectively these tools are integrated and their impact on costs, service quality, and regulatory scrutiny.
[Form 4] CVS HEALTH Corp Insider Trading Activity
CVS Health Director Fernando Aguirre reported the disposition of 32,000 shares of common stock back to the company in two transactions on May 20 and May 21, 2026. These transactions were classified as "Disposition to issuer" rather than open-market sales. After these dispositions, Aguirre directly holds 10,513 CVS common shares.
CVS (CVS) files S-3 shelf registration to offer debt securities
CVS Health Corporation has filed an S-3 shelf registration statement to periodically offer debt securities. This registration allows CVS to issue senior or subordinated debt, with specific terms to be detailed in future prospectus supplements. The net proceeds are intended for general corporate purposes, and the filing outlines covenants, potential events of default, and other critical financial provisions related to the debt offerings.
Kroger to lower prices on thousands of items to win back shoppers
Kroger plans to cut prices on thousands of products under new CEO Greg Foran to regain market share from competitors like Walmart, Costco, and Aldi. The grocery chain will reinvest savings from tighter sourcing, streamlined operations, and cost-cutting measures into lower prices and improved customer service. This strategy responds to increasingly cautious consumer spending due to inflation and economic uncertainty, as seen by Kroger's recent muted sales and profit growth forecast.
MetLife Inc. (NYSE: MET) Climbs to New 52-Week High
MetLife Inc. (NYSE: MET) reached a new 52-week high, with shares currently trading at $78.08, though daily volume is slightly below average. The financial services company offers diverse insurance, annuity, employee benefits, and asset management services globally across several segments. Its stock has fluctuated between a 52-week high of $83.85 and a low of $67.33, showing a 5.67% increase in the past week.
What drives multimillion-dollar medical claims? Sun Life report shows secondary health conditions, hospital stays and specialty drugs among key factors
A Sun Life U.S. report analyzing over 70,000 high-dollar medical claims reveals that secondary (comorbid) conditions, long inpatient hospitalizations, and injectable drugs are the primary drivers of medical claims exceeding $3 million. The report identifies orthopedic/musculoskeletal conditions, premature births, and cancer as common and costly conditions, with GLP-1s showing promise in reducing risks associated with high-dollar claims despite increased use. Sun Life emphasizes a whole-person care approach and offers various health support solutions to manage these rising healthcare costs.
CVS Health Corp. stock (US1266501006): Glenview trims stake after 80% total return and strong Q1 mom
Hedge fund Glenview Capital has reduced its stake in CVS Health Corp. after an 80% total return over two years, following strong first-quarter results and raised guidance, which helped the stock rebound sharply. Despite the profit-taking, CVS remains one of Glenview's top three holdings, signaling continued confidence in its long-term prospects. The article details CVS's integrated healthcare business model, recent financial performance, analyst sentiment, and its significance for US investors.
Total equity of CVS Health Corporation – BVL:CVSUS
This article provides access to the total equity data for CVS Health Corporation (CVSUS) on the Lima Stock Exchange via TradingView. It indicates that the market is closed with no current trades. The data is supported by various financial information providers like ICE Data Services and FactSet.
Glenview Capital sells 3.75M CVS shares, keeps it a top-3 holding
Glenview Capital has rebalanced its investment in CVS Health, selling 3.75 million shares after an 80% total return since May 2024. Despite this reduction for diversification, CVS remains one of Glenview's top three holdings, and the firm expresses strong confidence in its near, medium, and long-term outlook. The rebalancing followed healthy Q1 results and increased annual guidance for CVS.
Three major hospital systems accuse CVS of secretly siphoning hundreds of millions in drug savings
Three major hospital systems—Mount Sinai, University of Michigan Health (including Sparrow Hospital), and University of Kansas Hospital Authority—have filed lawsuits against CVS Health. They allege that CVS manipulated reimbursements from the federal 340B Drug Pricing Program, which enables hospitals to buy discounted medications to fund community health services, and siphoned hundreds of millions of dollars in savings for profit. The hospitals claim losses totaling over $249 million, citing CVS's alleged scheme to retain the difference between full price drug payments and reduced reimbursements to hospitals.
[144] CVS HEALTH Corp SEC Filing
This article reports a Form 144 SEC filing by CVS Health Corp, detailing the proposed sale of securities. The filing indicates the sale of 2,817 common shares with an aggregate market value of $263,886.42 through Charles Schwab Corp. The securities were acquired on May 2, 2023, as compensation from the issuer.
Third-party pixel use greatly increases healthcare data breach risk: study
A new study reveals that hospitals utilizing third-party tracking pixels are 46% more likely to experience a data breach. These pixels, common in other industries, raise significant HIPAA compliance and data privacy concerns in healthcare by transmitting sensitive patient information to external vendors. Researchers recommend that hospitals adopt homegrown, first-party tracking pixels to maintain control over data collection and mitigate the risk of unintended disclosures and security lapses.
CVS Health - You're Not Alone: Why Maternal Mental Health Matters
CVS Health emphasizes the critical importance of maternal mental health, noting that women make 80% of family health decisions but often face overlooked personal health challenges, including mental health conditions. Maternal mental health issues like postpartum depression are common and can have ripple effects beyond the mother, affecting bonding and care. The article advocates for integrating mental health into routine women's health care through screenings, expanded access, and clinician training to improve outcomes for families.
Hospitals allege contracted CVS Health subsidiaries pocketed their 340B savings
Several academic and nonprofit health systems have filed lawsuits against CVS Health and its subsidiaries, alleging they improperly retained approximately $250 million in 340B Drug Pricing Program savings between 2020 and 2025. The hospitals claim that CVS subsidiaries used their vertical integration as a pharmacy benefit manager, contract pharmacy, and third-party administrator to secretly lower reimbursement rates for discounted drugs, thereby diverting funds meant for safety-net providers. The plaintiffs are seeking financial recovery and full accountability from CVS Health.
Two USPSTF leaders fired, sparking concern about panel's credibility
Two U.S. Preventive Services Task Force (USPSTF) chairs were terminated by HHS Secretary Robert F. Kennedy Jr., raising concerns among public health experts about the panel's independence and its future. This move comes as the panel has not met for over a year, has many vacant seats, and the Trump Administration has shown interest in restructuring it. Industry professionals and organizations like AcademyHealth and the American Medical Association are advocating for a transparent and unbiased process for appointing new members to protect access to free preventive services mandated by the Affordable Care Act.
CVS Health, Diocese of Camden, and The Walters Group Unite to Bring Senior Affordable Housing to Williamstown, New Jersey
CVS Health has collaborated with The Diocesan Housing Services Corporation and The Walters Group to open The Mews at St. Mary, a new 75-unit senior affordable housing property in Williamstown, New Jersey. This initiative, backed by a $9 million investment from CVS Health, addresses the urgent need for affordable housing for older adults in the state. The property will offer integrated medical, social, and wellness services, building on CVS Health's broader commitment to improving community health and addressing housing insecurity across New Jersey.
CVS Pharmacy's retail model and U.S. store network explained
CVS Pharmacy functions as a significant U.S. drugstore brand, providing prescriptions, over-the-counter health items, and convenience goods through a vast national network. The company's retail model is described as a key component of its broader healthcare services, emphasizing convenience for consumers. This article explains the core functions of CVS Pharmacy and its importance within the American retail and healthcare landscape.
ProShare Advisors LLC Purchases 19,018 Shares of CVS Health Corporation $CVS
ProShare Advisors LLC increased its stake in CVS Health Corporation by 7.7% in the fourth quarter, acquiring an additional 19,018 shares, bringing its total holdings to 264,715 shares valued at $21.0 million. This comes as CVS Health reported strong quarterly results, exceeding revenue and earnings estimates, and raised its FY 2026 EPS guidance. Analysts generally maintain a positive outlook on the company, although insider Tilak Mandadi sold a significant number of shares.
COWZUS ETF Holdings List — BVL:COWZUS
This article provides the current holdings list for the Pacer US Cash Cows 100 ETF (COWZUS) as of May 21, 2026. It details the top ten holdings including companies like Qualcomm, CVS Health, Ford Motor, and Altria Group, along with their respective weight percentages, shares, and market values. The data aims to offer insights into the fund's composition.
CVS Health stock (US1266501006): Stable Q1 growth keeps focus on margins and US healthcare demand
CVS Health reported solid Q1 2026 revenue and earnings growth, with its stock trading in the mid-$90 USD range. Investors are monitoring margin trends, the integration of past acquisitions, and the company's full-year guidance within the US healthcare market. The vertically integrated model, combining retail pharmacy, PBM services, and health insurance, continues to drive performance, though regulatory scrutiny and competition remain key considerations.
CVS Health Stock Rallies 24% in a Month as Business Turnback Fuels Rebound
CVS Health Corp. (NYSE: CVS) has seen its shares jump 24% in the past month, driven by strong Q1 earnings, a turnaround in its insurance business, and positive analyst upgrades. The company reported better-than-expected revenue and EPS, leading to raised full-year guidance and highlighting improved business fundamentals across all three segments. Despite a notable debt load, analysts believe CVS is poised for further valuation increases due to its integrated healthcare model and attractive dividend yield, making it a compelling long-term investment.
CVS Health stock (US1266501006): Mizuho lifts price target as shares hover in mid?$90s
Mizuho has re-affirmed its Outperform rating on CVS Health stock (CVS) and increased its price target to $110 from $102, citing the company's long-term earnings potential. This update comes as CVS shares are trading around $94 on the NYSE. The article details CVS Health's diversified business model spanning retail pharmacies, pharmacy benefit management, and health insurance, highlighting its core revenue drivers and competitive position within the evolving U.S. healthcare market.
Strength in Danaher's Biotechnology Unit Seems Firm: More Upside Ahead?
Danaher Corporation's Biotechnology segment shows strong performance, with core revenues increasing 7% in Q1 2026 due to sustained momentum in bioprocessing and robust demand from pharmaceutical customers. Despite some headwinds in medical filtration and declining equipment demand, the company projects mid-single-digit core revenue growth for the segment in Q2 2026. Danaher's shares have declined recently, and its valuation is above the industry average, but its 2026 earnings estimate has seen an increase.
KU Hospital Authority says CVS stole nearly $62 million in prescription drug savings
The University of Kansas Hospital Authority has filed a lawsuit against CVS and its subsidiaries, alleging the company fraudulently diverted nearly $62 million in prescription drug savings intended for the federal 340B program between 2020 and 2025. The lawsuit claims CVS secretly kept these savings, which are meant to fund healthcare for low-income and uninsured patients, and retaliated by terminating its contract when the hospital requested an audit. CVS has declined to comment on the ongoing litigation.
Low digital health literacy hamstrings seniors' health IT use
A report from CVS Health reveals that low digital health literacy significantly impacts seniors, preventing 58% of Medicare enrollees aged 65 and older from fully managing their health. Despite this, 86% of seniors are open to using health IT, highlighting a crucial opportunity for healthcare organizations to implement human-led educational programs. The findings challenge the assumption that older adults are resistant to technology, emphasizing the need for accessible resources to bridge the digital health literacy gap.
Amer Sports Stock Surges on Q1 2026 Revenue Growth as Arc’teryx and Salomon Fire Together
Amer Sports (AS) experienced a significant surge in its stock price following robust Q1 2026 results, with revenue growing 32% year-over-year to $1.95 billion, largely driven by strong performances from its Arc’teryx and Salomon brands. The company also raised its full-year 2026 revenue growth guidance to 20-22% and adjusted diluted EPS guidance to $1.18-$1.23, indicating an improving financial outlook. TIKR's valuation model suggests a potential 136% upside, pricing AS stock at $80, despite assuming multiple compression.
KE Holdings Q1 2026: Operating Profit Jumps 45% While Revenue Falls 19%
KE Holdings (BEKE) reported a 45% year-over-year increase in non-GAAP operating profit in Q1 2026, reaching RMB 1.67 billion, despite a 19% decline in revenue to RMB 18.9 billion. This performance is attributed to the company's cost restructuring efforts from 2025, which led to significant margin expansion, with operating expenses hitting a three-year low. TIKR's valuation model suggests a 61% upside for BEKE stock, based on continued margin expansion and EPS growth rather than revenue recovery.
CVS Health pours $292M into veteran-run businesses and military families
CVS Health has announced its continued support for service members, veterans, and military families, detailing a comprehensive approach that includes healthcare access through TRICARE and MinuteClinic, community partnerships, well-being programs, and economic opportunities. The company spent $292 million in 2025 with veteran-owned small businesses and collaborates with various organizations to assist military-connected individuals throughout their lives. These efforts aim to provide stability, opportunity, and health, complementing CVS Health's broader growth and care-access initiatives.
Takeda faces $885m hit after landmark pay-for-delay lawsuit verdict
Takeda has been ordered to pay $885m, potentially rising to $2.5bn, after a US jury found the company liable in a "pay-for-delay" lawsuit related to its constipation drug, Amitiza. The lawsuit, filed by wholesalers and pharmacies, claimed Takeda entered an anticompetitive agreement with generic drugmaker Par Pharma to delay a cheaper version of the drug from reaching the market. Takeda has stated it will appeal the verdict, affirming its belief that the case lacks merit.
Mitsubishi UFJ Asset Management UK Ltd. Sells 12,000 Shares of CVS Health Corporation $CVS
Mitsubishi UFJ Asset Management UK Ltd. significantly reduced its stake in CVS Health Corporation by 75% in Q4, selling 12,000 shares and retaining 4,000 shares valued at $317,000. Despite this sell-off, CVS Health reported strong quarterly results, beating EPS and revenue estimates, and reaffirmed its FY 2026 EPS guidance. Analysts generally maintain a "Moderate Buy" rating for CVS, with several firms raising price targets.
CVS Health Corporation $CVS Shares Acquired by Northwestern Mutual Wealth Management Co.
Northwestern Mutual Wealth Management Co. significantly increased its stake in CVS Health Corporation, boosting its holdings by 129.1% to 296,795 shares. This comes as CVS Health reported strong first-quarter results, surpassing revenue and EPS expectations. Wall Street analysts largely maintain a "Buy" rating on CVS, with an average price target of $98.08, despite some recent insider selling.
CVS Health stock (US1266501006): investors weigh Q1 earnings, new strategy and steady dividend
CVS Health reported mixed Q1 2026 results, reaffirmed its full-year outlook, and continues to integrate its healthcare portfolio, encompassing retail pharmacies, pharmacy benefit management, and health insurance, while maintaining a consistent dividend. The company aims to manage patients across the entire care journey, positioning itself as a diversified healthcare group in a highly competitive and regulated US market. Its strategy focuses on growth drivers like pharmacy services, retail pharmacy, and health insurance, alongside new investments in primary and virtual care.
112,237 Shares in CVS Health Corporation $CVS Purchased by Fideuram Intesa Sanpaolo Private Banking S.P.A.
Fideuram Intesa Sanpaolo Private Banking S.P.A. recently acquired 112,237 shares of CVS Health Corporation, valued at approximately $8.9 million, during the fourth quarter. CVS Health continues to receive mostly positive ratings from analysts, with a "Moderate Buy" consensus and an average price target of $98.08. The company also announced strong quarterly results, beating EPS and revenue estimates, and raised its FY2026 guidance while maintaining its quarterly dividend.
106,518 Shares in CVS Health Corporation $CVS Acquired by Atle Fund Management AB
Atle Fund Management AB acquired a new stake of 106,518 shares in CVS Health Corporation, valued at approximately $8.45 million, making it the fund's 12th largest holding. CVS Health continues to receive broad institutional and analyst support, with 80.66% of its stock owned by hedge funds and institutions, and a consensus "Moderate Buy" rating from Wall Street. The company recently surpassed earnings expectations, reported strong revenue growth, and continues strategic initiatives like expanding pharmacist training and improving digital health literacy for Medicare members.
CVS Health stock (US1266501006): shares under pressure after guidance cut and restructuring push
CVS Health stock is under pressure after the company cut its 2026 earnings guidance and announced restructuring measures due to lower-than-expected profitability in its Health Care Benefits segment. The company is focusing on integrating its diverse assets and investing in digital tools to manage medical cost trends and improve efficiency, while also executing workforce reductions. This challenging environment requires close monitoring from investors given CVS Health's significant role in the US healthcare sector.
Berkshire Exit Puts Spotlight On UnitedHealth Earnings Strength And Regulatory Risks
Berkshire Hathaway has fully exited its stake in UnitedHealth Group (NYSE:UNH) after less than a year, prompting investors to re-evaluate the company's risk profile, particularly concerning regulatory scrutiny and cost pressures. While some see this as a red flag, other large institutions and analysts remain positive, citing UnitedHealth's scale and efficiency efforts. This exit amplifies attention on potential downside risks despite recent strong earnings and raised guidance.
CVS Pharmacy spots shape how Americans fill prescriptions
CVS Pharmacy is a vital retail health brand in the US, serving as a primary point for prescription pickup, vaccinations, and everyday health purchases. It integrates retail and healthcare, making it crucial for consumers, payers, employers, and health systems. The brand's US-centric model is shaped by specific regulations and insurance coverage, driving traffic to stores and impacting broader consumer behavior.
CVS Health collaborates with America250 to support the nation’s 250th anniversary celebration
CVS Health has announced its collaboration with America250, the national nonpartisan organization leading the commemoration of the 250th anniversary of the signing of the Declaration of Independence. This partnership will involve large-scale events, community giving programs, and exclusive merchandise, emphasizing CVS Health's commitment to advancing healthcare innovation and strengthening communities. With a significant national presence and economic impact, CVS Health aims to contribute to this historic milestone, reflecting its mission to simplify healthcare and improve access to care across the country.
CVS Health stock (US1266501006): Q1 earnings top estimates
CVS Health reported stronger-than-expected first-quarter 2026 earnings, with revenue of $100.43 billion and adjusted EPS of $2.57, surpassing Wall Street estimates. The stock is trading near its 52-week high, drawing attention from investors in the healthcare sector due to its integrated model of retail pharmacies, pharmacy benefit management, and health insurance. Despite positive earnings momentum and a steady dividend, the company still faces margin pressure and execution risks.
CVS offloads Omnicare pharmacy unit in $250m bankruptcy sale
CVS Health Corp. has received federal bankruptcy court approval for the $250 million sale of its Omnicare long-term care pharmacy subsidiary to GenieRx Holdings. This divestment is part of CVS's ongoing strategy to streamline its extensive healthcare portfolio, following other actions like job cuts in its Aetna unit. Despite these consolidations, CVS Health reported strong first-quarter financial results, with significant increases in net income and total revenue across all operating segments.
CVS Health Corporation $CVS Stock Holdings Decreased by Gabelli Funds LLC
Gabelli Funds LLC reduced its stake in CVS Health Corporation (NYSE:CVS) by 13.4% in the fourth quarter, selling 39,610 shares and holding 256,700 shares valued at approximately $20.4 million. Despite this reduction by one fund, institutional investors overall own 80.66% of the company's stock. Analysts remain largely positive on CVS Health, with a "Moderate Buy" rating and an average target price of $98.08 following strong Q4 earnings, which beat analyst estimates for both EPS and revenue.
iA Global Asset Management Inc. Invests $3.36 Million in CVS Health Corporation $CVS
iA Global Asset Management Inc. initiated a new position in CVS Health Corporation, purchasing 42,389 shares valued at approximately $3.36 million in the fourth quarter. This move comes as CVS Health reported strong quarterly results, exceeding analyst expectations for both EPS and revenue, and raising its full-year 2026 guidance. While analysts maintain a "Moderate Buy" rating for CVS, an executive vice president recently sold a significant number of shares.
Japan’s Takeda engaged in antitrust scheme to delay generic constipation drug, U.S. jury finds
A U.S. jury found Japan-based Takeda Pharmaceutical liable for approximately $885 million in damages for orchestrating an anticompetitive scheme to delay the release of a generic version of its constipation drug, Amitiza. The lawsuit, part of a wave of "pay-for-delay" cases, concluded that Takeda's settlement with Par Pharmaceutical in 2014 illegally postponed generic competition, causing pharmacies, insurers, health funds, and retailers to overpay for the drug. This verdict marks the first time a jury has found a pharmaceutical company liable in class action litigation over such agreements, with potential damages tripling under U.S. antitrust law.
Is Newell Brands (NWL) One of the Best Dividend Penny Stocks to Buy Right Now?
Newell Brands Inc. (NASDAQ: NWL) is listed among potential dividend penny stocks, with Deutsche Bank recently raising its price target to $4 from $3 while maintaining a Hold rating. The company's Q1 2026 earnings call revealed core sales growth across all segments, including a return to growth for Learning & Development, driven by improving consumer demand and strategic execution. Despite Newell's performance, the article suggests that other AI stocks might offer greater return potential in a shorter timeframe.
CVS Health Shareholders Approve New 2026 Incentive Plan
CVS Health shareholders have approved a new 2026 Incentive Compensation Plan, replacing the 2017 plan, which will govern future executive and employee awards. During their annual meeting on May 14, 2026, investors also re-elected all directors, ratified Ernst & Young LLP as the independent auditor, and supported executive pay, while rejecting a proposal to lower the threshold for written consent. TipRanks' AI Analyst, Spark, assesses CVS as Neutral, citing stable fundamentals but weaker margins, with a Buy rating and $106.00 price target from the most recent analyst.
Wellgistics Health Shares Jump 100% Ahead of Tuesday Earnings
Wellgistics Health's shares surged over 100% after the company withdrew preliminary proxy materials, signaling potential strategic deals and drawing investor attention ahead of its first-quarter earnings report on Tuesday. The Tampa-based firm is working to overhaul its capital structure and business, including a non-binding letter of intent to acquire WellCare Today for approximately $15 million, as it navigates Nasdaq's minimum bid requirements and liquidity concerns. The company faces stiff competition and challenges in its financial base, having reported a significant net loss in 2025.
CVS (CVS) investors back 2026 incentive plan and board, reject written-consent change
CVS Health Corporation's shareholders approved the 2026 Incentive Compensation Plan, elected all 13 director nominees, ratified Ernst & Young LLP as auditor, and approved executive compensation on an advisory basis at their Annual Meeting. Conversely, a stockholder proposal to lower the threshold for acting by written consent was rejected. These decisions indicate strong shareholder support for the current governance and compensation frameworks at CVS.
